Evidence map›Paper›PMID 34328581›Full record

ReviewCardiovascular drugs and therapy2023

The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic.

Michele Correale, Francesca Croella, Alessandra Leopizzi, Pietro Mazzeo, Lucia Tricarico, Adriana Mallardi, Martino Fortunato, Michele Magnesa, Vincenzo Ceci, Alessandra Puteo and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michele CorrealePoliclinico Riuniti University Hospital, Foggia, Italy.
Francesca CroellaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Alessandra LeopizziDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Pietro MazzeoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Lucia TricaricoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Adriana MallardiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Martino FortunatoDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Michele MagnesaDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Vincenzo CeciDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Alessandra PuteoPoliclinico Riuniti University Hospital, Foggia, Italy.
Massimo IacovielloDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Matteo Di BiaseDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. natale.brunetti@unifg.it.ORCID 0000-0001-9610-7408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 pandemic has negatively impacted the management of patients with acute and chronic cardiovascular disease: acute coronary syndrome patients were often not timely reperfused, heart failure patients not adequately followed up and titrated, atrial arrhythmias not efficaciously treated and became chronic. New phenotypes of cardiovascular patients were more and more frequent during COVID-19 pandemic and are expected to be even more frequent in the next future in the new world shaped by the pandemic. We therefore aimed to briefly summarize the main changes in the phenotype of cardiovascular patients in the COVID-19 era, focusing on new clinical challenges and possible therapeutic options.

Indexed as

Cardiovascular DiseasesCOVID-19HumansPandemicsPhenotypeSARS-CoV-2Acute coronary syndromeArrhythmiasCardiovascular diseaseCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Thrombosis; Heart failure

Identifiers

PMID34328581
PMCPMC8322635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.